Company Overview
Standard BioTools Inc. operates within the healthcare sector, specifically focusing on the medical devices industry where it provides essential instrumentation, consumables, and services to scientists and biomedical researchers globally. The company targets a diverse international customer base including markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific to support therapeutic development efforts. In terms of scale, the entity manages a market capitalization of $375.25M and generates total annual revenue of $85.33M based on trailing twelve-month data. The organization employs a workforce of 385 individuals to execute its operations, indicating a mid-sized enterprise structure typical for specialized biotechnology instrumentation providers. These financial figures suggest the company maintains a modest but established position in the niche market for laboratory equipment, with revenue levels that are significant relative to its market cap, reflecting high valuation multiples often seen in capital-intensive or research-dependent sectors.
Financial Health
The company reported revenue of $85.33M over the trailing twelve months, yet it recorded a net income loss of $-58,826,000 and an EBITDA of $-82,328,000, revealing a substantial disparity between top-line generation and profitability. This significant gap between revenue and net income indicates a heavy cost structure where operating expenses, likely driven by research and development or sales efforts in new markets, consume the majority of gross profits before reaching the bottom line. Free cash flow stands at $-171,834,880, which signals a negative cash generation scenario that limits the company's immediate financial flexibility and ability to fund operations solely from internal cash flows. The company holds cash reserves of $28.45M against total debt obligations of $111.65M, creating a net cash position that is negative by over $83M and suggesting a reliance on external financing. The debt-to-equity ratio is reported at 118.03, highlighting a highly leveraged balance sheet where debt significantly outweighs shareholder equity. Despite this leverage, the current ratio remains robust at 4.19, indicating strong short-term liquidity and the ability to cover current liabilities more than four times over with available assets. Return on Equity is negative at -13.1% and Return on Assets is -9.9%, metrics that demonstrate management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings and a forward P/E of -32.07, which implies the market prices in future earnings expectations that are not yet realized in current performance. The price-to-book ratio is 0.78, indicating that the stock trades at a discount relative to its book value, suggesting the market may be pricing in potential risks or anticipating a long path to profitability. Additionally, the price-to-sales ratio stands at 4.40 while the EV/EBITDA is -1.91, meaning investors are paying a significant multiple of sales for a company that currently incurs losses, a common valuation strategy for growth-stage biotech firms. The 52-week trading range spans from a low of $0.92 to a high of $1.72, providing a clear benchmark for recent price volatility and trading activity. Without a specific current price provided in the facts, the trading range defines the absolute bounds within which the stock has fluctuated over the past year. The beta value is 1.37, which indicates that the stock's price volatility is higher than the broader market, moving approximately 37% more aggressively than the market average during periods of fluctuation.
Growth & Income
Revenue growth year-over-year has contracted by -14.2%, while earnings growth is marked as N/A due to the company's continued unprofitability, meaning earnings are not growing in a traditional sense but rather reflecting deep structural losses. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm reinvests all available capital and generated cash flow back into operations, R&D, or debt reduction rather than distributing income to shareholders. The combination of negative revenue growth and negative earnings growth suggests the company is currently in a contractionary phase or investing heavily in areas that have not yet contributed to the bottom line. Overall, the growth and income profile is characterized by a lack of current profitability and dividend generation, relying instead on the hope that future product adoption or market expansion will reverse the negative trends in revenue and margins.